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Abstract
Background: To optimize the antitumor activity of oncrasin-1, a small molecule identified through synthetic lethality
screening on isogenic K-Ras mutant tumor cells, we developed several analogues and determined their antitumor activities.
Here we investigated in vitro and in vivo antitumor activity of NSC-743380 (1-[(3-chlorophenyl) methyl]-1H-indole-3-
methanol, oncrasin-72), one of most potent analogues of oncrasin-1.
Methodology and Principal Findings: In vitro antitumor activity was determined in NCI-60 cancer cell line panel using cell
viability assay. In vivo antitumor activity was determined in parallel with NSC-741909 (oncrasin-60) in xenograft tumors
established in nude mice from A498, a human renal cancer cell line. Changes in gene expression levels and signaling
pathway activities upon treatment with NSC-743380 were analyzed in breast and renal cancer cells by Western blot analysis.
Apoptosis was demonstrated by Western blot analysis and flow cytometric analysis. NSC-743380 is highly active against a
subset of cancer cell lines derived from human lung, colon, ovary, kidney, and breast cancers. The 50% growth-inhibitory
concentration (GI50) for eight of the most sensitive cell lines was #10 nM. In vivo study showed that NSC-743380 has a
better safety profile and greater antitumor activity than NSC-741909. Treatment with NSC-743380 caused complete
regression of A498 xenograft tumors in nude mice at the tested doses ranging from 67 mg/kg to 150 mg/kg. Mechanistic
characterization revealed that NSC-743380 suppressed the phosphorylation of C-terminal domain of RNA polymerase II,
induced JNK activation, inhibited JAK2/STAT3 phosphorylation and suppressed cyclin D1 expression in sensitive human
cancer cells. Blocking JNK activation or overexpression of constitutively active STAT3 partially blocked NSC-743380-induced
antitumor activity.
Conclusions: NSC-743380 induces antitumor activity through modulation of functions in multiple cancer related pathways
and could be a potential anticancer agent for some solid tumors.
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Introduction
Synthetic lethality screening has recently been used by various
investigators to identify genes that are crucial for survival of cer-
tain oncogene-transformed cells [1,2] or that sensitize cells to
chemotherapy [3], or small molecules that selectively induce cell
death in a subset of oncogene-transformed cells [4–6]. The
concept of synthetic lethality can be defined as a lethal phenotype
elicited by two events or mutations in two genes. For example,
mutations in an oncogene may render the cell vulnerable to a
functional change in another gene. Similarly, if a cell line contains
a mutation in one oncogene, synthetic lethality can be elicited by a
small molecule that induces or mimics biological functions of a
synthetic lethal mutation in the second gene. Thus, synthetic
lethality screening allows us to identify cytotoxic agents that are
lethal in cancer cells but not in isogenic normal counterparts.
Using synthetic lethality screening on isogenic cell lines with or
without a mutant K-Ras gene, we recently identified a small
molecule (designated oncrasin-1) that kills immortalized and
tumorigenic human ovarian epithelial cells expressing mutant K-
Ras but not cells expressing wild-type Ras genes [6]. To improve
antitumor activity of a compound identified through the screening
on a chemical library, we developed and tested several oncrasin-1
analogues. A few of them were found to be more active than
oncrasin-1 in sensitive cancer cells and were further evaluated for
their anticancer activities in NCI-60 cancer cell line panel. One of
these, NSC-741909 (1-[(4-chlorophenyl) methyl]-1H-indole-3-
methanol, oncrasin-60), was found to suppress the growth of
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28487several NCI-60 cancer cell lines with a unique anticancer spectrum
[7]. Mechanistic studies by reverse-phase protein microarray
(RPPA) revealed that treatment with NSC-741909 led to sustained
elevation of MAP kinase (P38 MAPK, ERK, and JNK)
phosphorylation by suppressing their dephosphorylation. Inhibi-
tion of JNK by its specific inhibitor or by dominant negative
constructs partially diminished NSC-741909–induced cell killing,
indicating that sustained activation of JNK induced by NSC-
741909 contributed to NSC-741909–mediated cell death [7].
NSC-743380 (1-[(3-chlorophenyl) methyl]-1H-indole-3-metha-
nol, oncrasin-72) is another potent analogue we identified during
analogue analysis for oncrasin-1. Here we report the in vitro activity
of NSC-743380 in the NCI-60 cancer cell line panel and the in vivo
activities of NSC-743380 and NSC-741909 in human xenograft
tumors in nude mice. NSC-743380 has similar anticancer
spectrum and activity as NSC-741909 in the NCI-60 cell line
panel. Interestingly, NSC-743380 has much better in vivo activity
and safety profiles than NSC-741909. Therefore, we further
investigated the mechanisms of NSC-743380-induced antitumor
activity. Our results showed that NSC-743380 may induce
antitumor activity by modulating the functions of multiple
cancer-related targets or pathways.
Results
Antitumor Activity of NSC-743380 in NCI-60 Cancer Cell
Line Panel
To optimize the compound we identified through synthetic
lethality screening, we evaluated several analogues with chemical
structures similar to that of oncrasin-1. We previously reported the
antitumor activity of an analogue, NSC-741909, in NCI-60 cancer
cell lines [7]. NSC-743380, another analogue with close structural
similarity to NSC-741909, was also evaluated in the NCI-60 cell
line panel. The only difference in chemical structure is that the
chlorine in NSC-741909 is in the p-position, whereas in NSC-
743380 it is in the n-position (Fig. 1). The tests performed by the
Developmental Therapeutics Program at the NCI showed that,
like NSC-741909, NSC-743380 is highly active against various
cancer cell lines from the lung, colon, ovary, kidney, and breast. In
58 of the 60 cancer cell lines tested, the median 50% growth-
inhibitory concentration (GI50) for NSC-743380 was 1.62 mM. For
eight of the most sensitive cell lines, the GI50 was #10
28 M
(10 nM), the lowest concentration tested by NCI (Fig. 1). The
anticancer spectrum and activity in the NCI-60 cell line panel are
very similar for NSC-741909 and NSC-743380.
In Vivo Activity of NSC-743380 and NSC-741909
A comparison analysis of the antitumor spectrum of NSC-
741909 in NCI-60 cell lines with those of well-studied anticancer
agents showed that NSC-741909 lies outside the category of
adequately studied classes of antitumor agents, suggesting that
NSC-741909 and NSC-743380 may have novel anticancer
mechanisms. We therefore performed in vivo activity tests on these
two compounds in a subcutaneous tumor model established from
A498, a renal cancer cell line, through collaboration with the
Developmental Therapeutics Program at NCI. An initial dose
tolerance test showed that, although NSC-743380 and NSC-
741909 have very close structural similarity, they have quite
Figure 1. Antitumor activity of NSC-743380 in the NCI-60 cancer cell line panel. A) The structure of NSC-743380. B) The 50% growth-
inhibitory concentrations (GI50) at logarithmic scale were calculated and are shown in the bar graph. The middle line represents the median GI50 for
NSC-743380 in NCI-60 cancer cell line panel.
doi:10.1371/journal.pone.0028487.g001
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intraperitoneal doses in mice for NSC-741909 and NSC-743380
on a daily 5 times schedule were 40 mg/kg and 150 mg/kg,
respectively. In the in vivo activity studies, therefore, NSC-741909
and NSC-743380 were given at different dose levels. NSC-741909
was administered at doses ranging from 17.9 mg/kg to 40 mg/kg,
whereas NSC-743380 was administered at doses ranging from
67 mg/kg to 150 mg/kg. Treatment with NSC-743380 caused
tumor regression at all three dose levels, and treatment with NSC-
741909 produced tumor regression or stabilization at the high and
intermediate dose levels (Fig. 2). Whereas all animals in the control
group were sacrificed due to tumor burden by day 61, all mice
treated with different doses of NSC-743380 survived at day 66
(Fig. 2B). A substantial number of animals treated with NSC-
743380 at all dose levels remained tumor free on day 66 (Fig. 2C).
No obvious toxic effects were observed in animals treated with
NSC-743380; however, some weight loss occurred in animals
treated with the high doses of NSC-741909 (Fig. S1). This result
not only demonstrates the in vivo activity of both compounds, it also
suggests that compounds of similar chemical structures with
similar in vitro activities may have dramatically different in vivo
activities and tolerances, highlighting the importance of optimizing
in vivo activities. Terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay revealed a remarkable apoptosis in
tumors harvested from NSC-743380 treated mice (100 mg/kg of
for 3 days), but not in tumors from solvent treated mice (Fig. 2D),
demonstrating effective in vivo apoptosis induction in xenograft
tumor tissues by NSC-743380.
Induction of Apoptosis by NSC-743380
The promising in vivo activity of NSC-743380 in the A498
tumor xenograft model prompted us to further investigate the
mechanisms of NSC-743380–induced antitumor activity in A498
cells. To determine whether the changes detected in A498 cells
were also applicable to other sensitive cells, we included MCF-7
cells in our studies. We also included 786-O and MDA-MB-231
cell lines that were resistant to NSC-743380 treatment in order to
detect differences in response between sensitive and resistant cells.
NSC-743380–induced dose-dependent growth inhibition was
evaluated in all four cell lines (two breast cancer cell lines and
two renal cancer cell lines). The results showed the IC50 for MCF-
7 and A498 were 0.02 mM and 0.01 mM, respectively, whereas the
IC50 for 786-O and MDA-MB-231 were higher than 10 mM (the
highest concentration we tested) (Fig. 3A).
Figure 2. Effect on subcutaneous A498 renal tumor xenografts. A) Median tumor weights of A498 human renal tumor xenografts in mice
receiving vehicle control, NSC-743380 or NSC-741909 treatment. Data are presented with the standard errors of the median shown as error bars. Each
treatment group comprised 8 mice, and the control group 16. All treatment groups were statistically significantly different (Student’s t test) from the
control at multiple time points. B) Kaplan Meier Survive Curve of the animals shown in A. C) The numbers of tumor-free mice at day 66. D) TUNEL and
DAPI staining of tumors treated with solvent or NSC-743380 (100 mg/kg).
doi:10.1371/journal.pone.0028487.g002
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due to induction of apoptosis or growth inhibition, we performed
cell cycle analysis on the same four cell lines after treatment with
NSC-743380 (0.01–1 mM) (Fig. 3B). The sub-G1 populations were
increased in a dose-dependent manner in A498 and MCF-7 cells
(Fig. 3C). In contrast, there was no significant change in sub-G1
populations in 786-O and MDA-MB-231 cells after NSC-743380
treatment. This indicates that NSC-743380 can effectively induce
apoptosis in sensitive cells. Western blot analysis showed that
treatment with 1 mM NSC-743380 effectively activated caspase-8
and caspase 9 in MCF-7 and A498 cells (Fig. 3D), indicating that
its cytotoxic effect in cancer cells is due to its induction of
apoptosis. No cleaved caspase-8 or caspase-9 could be detected in
resistant 786-O and MDA-MB-231 cells at 1 mM NSC-743380.
NSC-743380 Modulates Functions of Multiple
Cancer-Related Pathways
To further determine molecular mechanisms of NSC-743380
induced antitumor activity, we investigated effects of NSC-743380
on phosphorylation of RNA polymerase II and various cancer-
related pathways, including basal and phosphorylated levels of
growth factor receptors, Src tyrosine kinase, JNK and ERK1/2,
STAT3, JAK2, cyclin B1 and cyclin D1, in sensitive and resistant
cells after treatment with 1 mM NSC-743380 for 12 h. The results
show that, like the leader compound oncrasin-1 [8], NSC-743380
could effectively inhibit phosphorylation of RNA polymerase II
(Fig. 4A). Moreover, the levels of phosphorylated JNK (Thr181/
Tyr185) and ERK1/2 (Thr202/Tyr204) were increased in
sensitive cells after treatment, but not in resistant cells. Further-
more, the levels of phospho-EGFR (Tyr1068), phospho-Src
(Tyr416), phospho-STAT3 (Tyr705), JAK2 (Try1007/1008) and
cyclin D1 were decreased in sensitive cells but not in resistant cells.
No significant changes were observed in cyclin B, total JNK, Erk,
Src, STAT3, or JAK2 after NSC-743380 treatment. This result
suggested that treatment with NSC-743380 induced functional
changes in multiple pathways, including mRNA elongation/
processing, EGFR, JNK, Erk, Src, and JAK2/STAT3 pathways.
We then tested the time dependency of the above molecular
changes. Cells were treated with 1 mM NSC-743380 for 2–12 h,
and cell lysates were subjected to Western blot analysis. The results
showed that the decrease in phosphorylation of JAK2 and STAT3
occurred relatively earlier (2–4 h) than the decreases in Src
phosphorylation, and phosphorylated EGFR, suggesting that
inhibition of JAK2 and STAT3 (Y705) might be Src- or EGFR-
independent (Fig. 4B). The decrease of cyclin D1 and phosphor-
ylated RNA polymerase II occurred at 4–8 h after the treatment.
We also evaluated the dose effect on RNA polymerase II, JAK2/
STAT3 and cyclin D1 in two sensitive cell lines and found that
cyclin D1 and the phosphorylation of RNA polymerase II, JAK2
Figure 3. Induction of apoptosis by NSC-743380. Two renal cancer cell lines (786-O and A498) and two breast cancer cell lines (MCF-7 and
MDA-MD-231) were treated with different doses of NSC-743380. Cells treated with DMSO were used as controls. Cell viability was assayed 72 h after
treatment by the SRB method. Apoptotic cells were determined by flow cytometric analysis 24 h after treatment. A) Cell viability assay. Viability of
control cells was set as 1. Each data point represents the mean 6 SD of three independent experiments. B) Histogram of cell cycle analysis at 24 h
after treatment with 1 mM NSC-743380. C) Percentages of apoptotic cells. The values represent the means 6 SD of three analyses. D) The four cell
lines were treated with 1 mM NSC-743380 for 12 h. Whole-cell lysates were harvested for Western blot analysis of caspase-8 cleavage and cleaved
caspase 9. C: controls; T: treated with NSC-743380.
doi:10.1371/journal.pone.0028487.g003
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(Fig. 4C). Together, these data suggest that NSC-743380 modu-
lating multiple targets in signaling pathways at time- and dose-
dependent manners.
Because MAPK pathway activation was reported to inhibit
STAT3 phosphorylation at site Tyr705 [9] and NSC-743380
induced dramatic increases in pJNK and pERK, we tested
whether pretreating MCF7 cells with the JNK inhibitor II
(SP600125) or a MEK inhibitor (U0126) at 10 mM for 2 h would
block NSC-743380–induced inhibition of STAT3 phosphoryla-
tion at site Tyr705. The results showed that blocking NSC-
743380–induced JNK and ERK activation did not affect NSC-
743380–mediated STAT3 suppression (Fig. 5A), suggesting that
NSC-743380-induced STAT3 inhibition is not associated with
MAPK activation. We also investigated whether suppression of
STAT3 could have impact on JNK activation or RNA polymerase
II suppression. For this purpose, we treated A498 and MCF-7 cells
with STAT3 siRNA and determined the effect on JNK activation
and RNA polymerase II suppression. Knockdown of STAT3
alone did not induce JNK activation and had minimal effect on
RNA polymerase II phosphorylation (Fig. 5B), suggesting that
NSC-743380-induced effects on JNK, STAT3 and RNA poly-
merase II could be independent.
JNK inhibitor or Constitutively Active STAT3 Partially
Diminished NSC-743380-induced Cell Killing
To investigate the role of JNK activation and STAT3 inhibition
in NSC-743380–induced apoptosis, we determined that the cell
killing effect of NSC-743380 in A498 cells after cells were
pretreated with a JNK inhibitor SP600125 [10] or a constitutively
active STAT3. NSC-743380 induced cell growth inhibition was
partially reversed at the presence of JNK inhibitor SP600125, but
was not affected by the presence of p38 MAP kinase inhibitor
SB203580 or Erk inhibitor U0126 (Fig. 6A), suggesting that
inhibiting JNK activation could partially reverse the antitumor
activity of NSC-743380. Stably transfected A498 cells with con-
stitutively active STAT3 (STAT3-CA) but not dominant negative
STAT3 (STAT3-DN) also partially reverses NSC-743380 induced
antitumor activity (Fig. 6B). The IC50 for NSC-743380 in STAT3-
CA A498 cells increased to 0.15 mM, whereas IC50 in parental
cells was 0.01 mM. We also performed fluorescence-activated cell
sorting analysis to test the percentage of apoptotic cells and cell
viability assay 12 h after treatment with 1 mM NSC-743380 in
A498 cells that were stably transfected with STAT3-DN or
STAT3-CA constructs (Fig. 6C, and Fig. S3). The result showed
STAT3-CA diminished NSC-743380 induced apoptosis whereas
STAT3-DN increased the apoptosis. This result suggested that
both JNK activation and STAT3 inhibition contributed to NSC-
743380 induced antitumor activity and that functional reversal of
either pathway could only partially affect NSC-7433380’s
anticancer activity.
Discussion
Our results demonstrate that NSC-743380 has potential in vitro
and in vivo antitumor activities and that NSC-743380 modulates
Figure 4. Modulating functions of multiple pathways by NSC-743380. A) Changes in molecular markers of various pathways after treatment
with 1 mM NSC-743380 for 12 h in breast and renal cancer cells. C: controls; T: cells treated with NSC-743380. B) Time-dependent changes in p-EGFR,
p-Src, p-JAK2, and p-STAT3 in A498 and MCF-7 cells after treatment with 1 mM NSC-743380. C) Dose-dependent changes in p-EGFR, p-Src, p-JAK2, and
p-STAT3 in A498 and MCF-7 cells after treatment with different doses of NSC-743380 for 12 h.
doi:10.1371/journal.pone.0028487.g004
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phosphorylation, activating MAP kinase JNK, and inhibiting
JAK/STAT3 pathway, all of which play critical roles in anticancer
therapy and/or tumorigenesis. Although the two sensitive cell lines
used in the mechanistic study have wild type p53 while the two
resistant cell lines have mutant p53, the status of p53 gene
mutation is likely not a critical factor in NSC-743380 induced
apoptosis, because a number of p53 mutant cancer cell lines in
NCI-60 panel were highly susceptible to NSC-743380. For
example, renal cancer cell line TK-10 and breast cancer cell line
T-47D are both p53 mutant and highly sensitive to NSC-743380
(Fig. 1).
Evidence has indicated that oncogene-transformed cells require
continuous activity of RNA polymerase II to prevent oncogene-
induced apoptosis [11]. Anticancer agents such as the pan-cyclin
dependent kinase (CDK) inhibitors flavopiridol and seliciclib elicit
their antitumor activity by inhibiting RNA polymerase II [12–14],
leading to suppression of the expression of short-lived antiapoptotic
proteins such as Mcl-1, XIAP, Bcl-XL, and survivin [15–17],
suggesting that RNA polymerase II may serve as a therapeutic
target for cancers. The effect of NSC-743380 on RNA polymerase
II phosphorylation suggests that it may affect mRNA transcription
in general. Indeed, mRNA levels of cyclin D1 and cyclin B1 were
both reduced insensitivecellsafterNSC-743380treatment(TextS2
and Fig. S2), although there was no detectable changes of cyclin B1
at the protein level. Similarly, JNK is an important mediator of
apoptosis caused by various stress stimuli and anticancer agents
[18–20]. JNK has been reported to suppress Ras transformation
through apoptotic elimination of Ras-transformed cells in vivo [21].
Dominant negative mutations in JNK signaling pathway is
associated with human cancers [22]. Activation of JNK leads to
phosphorylation of Bcl2 and Bcl-XL [18] and accelerates
degradation of the NF-kappaB-induced antiapoptotic protein c-
FLIP through phosphorylation and activation of E3 ubiquitin ligase
Itch [23], facilitating apoptosis induction. The partial reversal of
NSC-743380induced antitumoractivity bya JNK-specificinhibitor
suggested that NSC-743380 induced antitumor activity is both
JNK-dependent and –independent.
Signal transducer and activator of transcription 3 (STAT3) is a
key regulator of gene expression and is activated by tyrosine
Figure 5. Independent effects on JNK, STAT3 and RNA polymerase II induced by NSC-743380. A) Effect of JNK and ERK inhibitors. MCF-7
cells were treated 1 mM NSC-743380 in the presence or absence of 10 mM SP600125 or 10 mM U0126 and examined for expression of p-ERK, p-JNK,
and p-STAT3 (Tyr705 and Ser727). Whole-cell lysates were subjected to Western blot analysis, and b-actin was used as the loading control. B) Effect of
STAT3 knockdown. After transfected with control RNAi or STAT3 RNAi for 48 hours, A498 and MCF7 were treated with 1 mM NSC-743380 for 6 hours.
Phosphorylation of JNK, STAT3 and PloII were determined by Western Blot analysis. b-actin was used as the loading control.
doi:10.1371/journal.pone.0028487.g005
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other tyrosine kinase families in response to a variety of cytokines
and growth factors [24]. JAK/STAT3 has been implicated in
oncogenesis, invasiveness and metastasis of some types of cancers
[25–27]. Efforts have been made in developing small molecule
inhibitors of STAT3 and JAK for cancer therapy [28–30] and
some of them showed good in vitro and in vivo antitumor activities.
Our study showed that NSC-743380 suppressed phosphorylation
and activation of JAK2/STAT3 and that NSC-743380–mediated
inhibition of STAT3 may contribute partially to NSC-743380–
induced antitumor activity, because this antitumor activity was
partially diminished when sensitive cells were transfected with a
constitutively active STAT3.
Our results suggested that NSC-743380 selectively modulates
functions of RNA polymerase II, JNK, and JAK/STAT3
pathways in a subset of cancer cells, because the functionality of
those molecules was not affected by NSC-743380 in the resistant
cancer cell lines. The mechanisms underlining the selectivity of
NSC-743380 in cancer cells were not clear. NSC-743380 may not
directly inhibit kinases because a test on 300 kinases by Reaction
Biology Corporation (Malverin, PA) showed that, at 1 mM
concentration, NSC-743380 did not have appreciable inhibitory
effect (or more than 25% inhibition) on those tested kinases (data
not shown). Nevertheless, our data suggest that NSC-743380–
mediated STAT3 inhibition is not associated with JNK activation,
because blocking NSC-743380–induced JNK or ERK phosphor-
ylation had no effect on NSC-743380–mediated inhibition of
STAT3. Similarly, knockdown of STAT3 had minimal effect on
JNK activation and RNA polymerase inhibition. Together, those
results suggest that NSC-743380 may modulate functions of
multiple cancer related pathways.
The in vivo activity studies reported here show that NSC-743380
is highly active against established xenograft tumors derived from
A498 renal cancer cells. The favorable in vivo activity induced by
this compound at doses without obvious toxicity suggests the
possibility of translating this compound for clinical evaluation.
Interestingly, although NSC-743380 and NSC-741909 have very
similar structures and in vitro activities, including their anticancer
Figure 6. Effect of JNK inhibitor and constitutive STAT3 on NSC-743380-induced cell killing. A) A498 cells were pretreated with 10 mMo f
JNK inhibitor SP600125, p38 MAP kinase inhibitor SB203580 or Erk inhibitor U0126 for 2 hours, and then analyzed for their susceptibility to NSC-
743380. Dose response to NSC-743380 was determined by the SRB assay. Values represent the means 6 SD from three independent experiments. B)
A498 cells were transfected with a plasmid expressing STAT3-CA or expressing STAT3-DN. After selection with G418, cells expressing STAT3-CA or
STAT3-DN were pooled together. Parental, STAT3-CA–transfected, or STAT3-DN–transfected A498 cells were then analyzed for their susceptibility to
NSC-743380. Dose response to NSC-743380 was determined by the SRB assay. C) Percentage of apoptotic cells in parental and STAT3-CA or STAT3-DN
transfected A498 cells at 12 h after treatment with 1 mM NSC-743380. * represents a P value less than or equal to 0.05. D) Putative mode of action by
NSC-743380.
doi:10.1371/journal.pone.0028487.g006
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vivo toxicity and activity profiles. These in vivo results also highlight
the importance of compound optimization in vivo.
Materials and Methods
Cell Lines
The human breast cancer cell lines (MDA-MB-231 and MCF-7)
and human renal cancer cell lines (A498 and 786-O) were grown
in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum and 100 mg/mL penicillin-streptomycin (all
from Life Technologies, Gaithersburg, MD). All four cell lines
used in the mechanistic study were mycoplasma-free when tested
by a polymerase chain reaction (PCR)-based Mycoplasma Test
[31,32].
Chemicals and Antibodies
NSC-743380 (1-[(3-chlorophenyl) methyl]-1H-indole-3-metha-
nol, C16H14ClNO, MW 271.7) and NSC-741909 (1-[(4-chloro-
phenyl) methyl]-1H-indole-3-methanol, C16H14ClNO, MW
271.7) used for in vivo study were synthesized by Developmental
Therapeutics Program at NCI. NSC-73380 used for in vitro study
was synthesized as previously described [33] and has purity of
$98%. The purity was determined by high-performance liquid
chromatography (Agilent Technologies 1200 Series) equipped with
a C-18 bounded-phase column (Waters, XTerra C18 MS, 3.5 mm,
4.5650 mm). A gradient elution was performed with acetonitrile
and water as a mobile phase and was monitored at 230 nm. The
chemical entity of NSC743380 was determined by LC/MS/
UV230 and
1H and
13C NMR analyses (Text S1). Electrospray
ionization (ESI) MS spectra were recorded with an Agilent LC/
MSD Trap XCT Ultra spectrometer. NMR spectra were recorded
with Bruker Avance DRX 300 spectrometer.
Inhibitors of JNK (SP600125) and MEK (U0126) were
purchased from EMD Chemicals (Gibbstown, NJ). Antibodies to
the following proteins were used for Western blot analysis: JNK,
phospho-JNK, STAT3, phospho-STAT3, phospho-JAK2, phos-
pho-Src-416, Phospho-src-527, cleaved caspase 9, cyclin B, and
cyclin D1 (Cell Signaling Technology, Danvers, MA), caspase-8
(Alexis Biochemicals, Farmingdale, NY), and b-actin (Sigma-
Aldrich, St. Louis, MO).
Cell Viability Assay
Cell viability was determined by the sulforhodamine B (SRB)
assay as previously reported [6]. Relative viability of the treated
cells was normalized to the DMSO-treated control cells, which
were set at 1. Each experiment was performed in quadruplicate
and repeated at least three times. The IC50 value, a dose that
causes a 50% reduction in surviving cells after 72 hours treatment
compared with that of control cells, was calculated by using the
CurveExpert Version 1.3 program.
Flow Cytometry Assay
Cells were seeded at a density of 2.5610
5 cells/well in six-well
plates and allowed to grow overnight. After treatment, cells were
harvested with trypsin and washed twice with phosphate-buffered
saline solution (PBS). Cells were fixed with 75% ethanol at a
density of 1610
6 cells/mL overnight. The cell pellets were then
harvested and resuspended with propidium iodide (BD Bioscienc-
es, San Hose, CA) for 15 min in the dark at room temperature.
The cells were analyzed on an EPICS Profile II flow cytometer
(Beckman Coulter, Brea, CA) with the Multicycle Phoenix Flow
Systems program (Phoenix Flow Systems, San Diego, CA). All
experiments were repeated three times.
Western Blot Analysis
Western blot analysis was performed as we reported previously
[8]. Briefly, cells were harvested and subjected to Laemmli’s lysis
buffer, and the protein concentration was determined by using the
Bradford method. Equal amounts of lysate (40 mg) were separated
by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and then transferred to Hybond-enhanced chemiluminescence
membranes (GE Healthcare Life Sciences, Piscataway, NJ).
Membranes were blocked with PBS containing 5% low-fat milk
for 1 h and incubated with primary antibodies overnight at 4uC.
After three washes with PBS containing 0.1% Tween-20,
membranes were incubated with IRDye infrared secondary
antibodies for 1 h at room temperature. The membranes were
washed with PBS Tween-20 again and detected with the Odyssey
Infrared Imaging System (Lincoln, NE). b-Actin was used as a
loading control.
Plasmid Transfection and Stable Cell Lines
The plasmids expressing STAT3-CA or STAT3-DN were
kindly provided by Dr. James Darnell [25]. Plasmid or siRNA
oligonucleotides transfection was performed as previously de-
scribed [7]. Control RNAi and STAT3 RNAi were purchased
from Dharmacon Products (Lafayette,CO). Stable transfectants
were selected with a medium containing 500 mg/mL G418.
Plasmid transfection was performed with FuGENE6 reagent
(Roche Diagnostics, Indianapolis, IN).
Animal Experiments
In vivo antitumor activity assays were performed by the
Experimental Therapeutics Program at the NCI. Six-week-old
female athymic nude mice (Animal Production Program, Freder-
ick, MD) were implanted with A498 tumor fragments obtained
from serially passaged donor mice. The tumors, initiated by
subcutaneous injection of 10
7 A498 cells (DCTD Repository,
Frederick, MD), were at third in vivo passage for this study. When
the tumors reached approximately 125 mg, the mice were
randomized into treatment groups and therapy was initiated.
Tumor growth was monitored by caliper measurements, and
tumor weights were calculated as: [tumor length in mm6(tumor
width
2 in mm)]/2=weight in mg [34]. The treatments were
administered intraperitoneally once daily for a total of 14 days.
The control group (n=16) received 10% DMSO in 0.09% saline
solution with 0.05% Tween-80 in a dose volume of 0.1 mL/10 g
body weight. The experimental treatments (n=8/group) included
NSC-743380 at doses of 150 mg/kg, 100 mg/kg, 67 mg/kg. The
dosing solutions were prepared fresh daily by dissolving a known
weight of test material in 100% DMSO and subsequently diluting
the 106stock into 0.9% saline solution containing 0.05% Tween-
80. Tumor growth and animal body weight were monitored
overtime. All treatments were administered on an exact body
weight basis using a dose volume of 10 mL/kg of body weight.
NSC-743380 was evaluated as suspensions as they were not
soluble at the concentrations necessary to achieve the desired doses
in mice. The mice were monitored for 66 days after treatment
began. The results were evaluated as described previously [34] by
measuring tumor volumes and counting tumor-free survivors.
TUNEL assay
Tumors were established as described above and were allowed
to grow to a size of 0.5–0.8 cm
3 before treatment started. Mice
bearing A498 tumors were then treated daily with solvent or
100 mg/kg NSC-743380 (n=3 animals per group) for 3 days.
Four hours after the last dose, animals were euthanized, and
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medium. The tissue blocks were stored at 280uC until ready for
sectioning. The TUNEL assay was performed following the
manufacturer’s instructions of a kit from Promega (DeadEndTM
Fluorometric TUNEL System). The slides were evaluated under
fluorescence microscopy for apoptotic cells with a strong green
nuclear fluorescence. Nucleus staining with DAPI which exhibits a
blue nuclear fluorescence was used an indicator for the presence of
cells.
Statistical Analysis
Differences between the treatment groups were assessed by
ANOVA and followed by student t test using the software StatSoft.
The data on tumor-free survivors were evaluated by Fisher exact
test comparing the treated groups to vehicle control groups on day
66. All tests were two-tailed. P-values less than 0.05 were
considered statistically significant.
Supporting Information
Figure S1 Body weights of mice treated with NSC-
743380 or NSC-741909. Data presented are the mean body
weights of mice shown in Figure 2. The mice bearing
subcutaneous A498 renal tumor xenografts were treated with
vehicle control, NSC-743380 or NSC-741909 at the doses as
indicated. Each treatment group had 8 mice while the control
group 16 mice.
(TIF)
Figure S2 mRNA levels of Cyclin D1 and Cyclin B1
expression after treatment with NSC-743380. A) Time
dependent and dose response changes of Cyclin D1 mRNA after
treatment with NSC-743380 in A498 cells. B) Dose dependent
changes of Cyclin B1 mRNA after treatment with NSC-743380 in
A498 cells. The mRNA levels were normalized with that of
GAPDH.
(TIF)
Figure S3 Cell viability of A498, A498 STAT3-CA and
A498 STAT3-DN cells after treatment with 1 mM NSC-
743380 for 12 h. Cells treated with DMSO were used as controls
and set as 1. Cell viability was assayed 12 h after treatment by the
SRB method. Each data point represents the mean 6 SD of three
independent experiments.
(TIF)
Text S1 Method for synthesis, purity determination
and structure identification of NSC-743380.
(DOCX)
Text S2 Quantitative PCR for mRNA analysis.
(DOCX)
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